Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Exploring a new pathway for biomarker-based approval of immunotherapies

Nature Reviews Clinical Oncology volume 20, pages 279–280 (2023)Cite this article

Subjects

The revolution of immunotherapies in oncology has not been matched by the development of companion diagnostic biomarkers able to identify the ideal target populations. Aside from the established pathways for regulatory approval relying on predefined biomarkers, a novel approach based on post hoc biomarker analysis could potentially be instrumental in enhancing the cost-effectiveness of cancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Current pathways for FDA approval of companion diagnostic biomarkers for cancer therapies.

References

  1. Cherny, N. I. An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed? Nat. Rev. Clin. Oncol. 19, 486–492 (2022).

    Article  PubMed  Google Scholar 

  2. Subbiah, V. et al. Accelerated approvals hit the target in precision oncology. Nat. Med. 28, 1976–1979 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151–172 (2022).

    Article  CAS  PubMed  Google Scholar 

  4. Llovet, J. M. et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat. Cancer 3, 386–401 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Montironi, C. et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 72, 129–140 (2023).

    Article  CAS  PubMed  Google Scholar 

  7. Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599–1611 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Jørgensen, J. T. The current landscape of the FDA approved companion diagnostics. Transl Oncol. 14, 101063 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Amatya, A. K. et al. Subgroup analyses in oncology trials: regulatory considerations and case examples. Clin. Cancer Res. 27, 5753–5756 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011–2019 (2011).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The work of J.M.L. is supported by grants from the US NIH (RO1DK56621 and RO1DK128289), Cancer Research UK, Fondazione AIRC and Fundación Científica de la Asociación Española Contra el Cáncer (HUNTER, ref. C9380/A26813), the Samuel Waxman Cancer Research Foundation, Generalitat de Catalunya (AGAUR, SGR-1358), and the Spanish National Health Institute (MICINN, PID2019-105378RB-I00).

Author information

Authors and Affiliations

  1. Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Josep M. Llovet

  2. Translational Research in Hepatic Oncology, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain

    Josep M. Llovet

  3. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

    Josep M. Llovet

Authors
  1. Josep M. Llovet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep M. Llovet.

Ethics declarations

Competing interests

J.M.L. has received research support from Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai and Ipsen, and consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bluejay Therapeutics, Boston Scientific, Bristol Myers Squibb, Captor Therapeutics, Eisai, Eli Lilly, Exelixis, Genentech, Glycotest, Ipsen, Merck, Mina Alpha, Omega Therapeutics and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Llovet, J.M. Exploring a new pathway for biomarker-based approval of immunotherapies. Nat Rev Clin Oncol 20, 279–280 (2023). https://doi.org/10.1038/s41571-023-00731-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00731-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer